[Federal Register Volume 76, Number 147 (Monday, August 1, 2011)]
[Notices]
[Pages 45838-45839]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-19378]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Combination Cancer Therapy Using an IL13-Targeted Toxin and a Vaccine
Description of Technology: Typical cancer treatments such as
chemotherapy, radiation therapy and surgical resection are non-specific
processes that kill healthy cells as well as diseased cells, ultimately
resulting in discomfort and undesirable side-effects for patients. In
an effort to reduce the burden on cancer patients, a tremendous effort
has been placed on developing ways to increase the specificity of
cancer treatments. One way to increase specificity is to identify
proteins which are present on the surface of cancer cells but absent on
normal healthy cells, and use that protein as a target for delivering a
therapeutic agent. Because the therapeutic agent only reaches the
diseased cell, patients are less likely to experience non-specific
side-effects, reducing their pain burden during treatment.
IL13-receptor-alpha-2 (IL13-R[alpha]2) is a cell surface protein
that is selectively expressed on certain diseased cells, including
cancer cells. IL13-R[alpha]2 binds to the cytokine IL13, suggesting
that a therapeutic agent fused to IL13 can target and kill only those
cancer cells which express IL13-R[alpha]2. Our inventors previously
constructed fusion proteins comprising (1) IL13 and (2) an active
fragment of the bacterial toxin Pseudomonas exotoxin A (PE). These
IL13-PE fusion proteins demonstrated the ability to selectively kill
cancer cells that overexpressed IL13-R[alpha]2, as well as other types
of diseased cells (asthma, pulmonary fibrosis) which overexpressed
IL13-R[alpha]2. This suggested that IL13-PE fusion proteins were
excellent candidates for new therapeutic agents.
The inventors recently sought methods to increase the effectiveness
of these IL13-PE fusion proteins in the treatment of disease. This
technology is directed to a combination therapy comprising (a) a DNA
vaccine against IL13-R[alpha]2 and (b) an IL13-PE fusion protein. By
combining these therapeutic approaches it is possible to kill certain
cell types that express IL13-R[alpha]2 at high levels (such as cancer
cells), making this combinatorial approach an attractive potential
therapeutic.
Applications:
Treatment of diseases associated with the increased
expression of IL13-R[alpha]2
Relevant diseases include pulmonary fibrosis, asthma and
cancers such as pancreatic cancer, glioblastoma multiforme and other
head and neck cancers
Advantages:
The DNA vaccine only affects cells where IL13-R[alpha]2
expression is increased, limiting their effects to diseased cells
IL13-PE fusion proteins also only kill cells that
overexpress IL13-R[alpha]2, allowing specific targeting of treatment
Targeted treatment decreases non-specific killing of
healthy, essential cells, resulting in fewer side-effects and healthier
patients
Development Status: Preclinical stage of development.
Inventors: Puri et al. (FDA).
Patent Status: US provisional application 61/451,331 (HHS reference
E-104-2011/0-US-01).
For more information, see:
US Patents 5,614,191, 5,919,456 and 6,518,061 (HHS
technology reference E-266-1994/0)
US Patent Publication US 20040136959 A1 (HHS technology
reference E-032-2000/0)
US Patent 7,541,040 (HHS technology reference E-296-2001/
0)
Licensing Status: Available for licensing.
Licensing Contact: David A. Lambertson, PhD; 301-435-4632;
[email protected].
[[Page 45839]]
Combination Cancer Therapy Using an IL13-Targeted Toxin and an HDAC
Inhibitor
Description of Technology: Typical cancer treatments such as
chemotherapy, radiation therapy and surgical resection are non-specific
processes that kill healthy cells as well as diseased cells, ultimately
resulting in discomfort and undesirable side-effects for patients. In
an effort to reduce the burden on cancer patients, a tremendous effort
has been placed on developing ways to increase the specificity of
cancer treatments. One way to increase specificity is to identify
proteins which are present on the surface of cancer cells but absent on
normal healthy cells, and use that protein as a target for delivering a
therapeutic agent. Because the therapeutic agent only reaches the
diseased cell, patients are less likely to experience non-specific
side-effects, reducing their pain burden during treatment.
IL13-receptor-alpha-2 (IL13-R[alpha]2) is a cell surface protein
that is selectively expressed on certain diseased cells, including
cancer cells. IL13-R[alpha]2 binds to the cytokine IL13, suggesting
that a therapeutic agent fused to IL13 can target and kill only those
cancer cells which express IL13-R[alpha]2. Our inventors previously
constructed fusion proteins comprising (1) IL13 and (2) an active
fragment of the bacterial toxin Pseudomonas exotoxin A (PE). These
IL13-PE fusion proteins demonstrated the ability to selectively kill
cancer cells that overexpressed IL13-R[alpha]2, as well as other types
of diseased cells (asthma, pulmonary fibrosis) which overexpressed
IL13-R[alpha]2. This suggested that IL13-PE fusion proteins were
excellent candidates for new therapeutic agents.
In an effort to increase the effectiveness of these IL13-PE fusion
proteins, the inventors sought ways to increase the expression of IL13-
R[alpha]2 on cancer cells, thereby increasing the rate at which the
therapeutic agent could kill the diseased cell. Histone deacetylase
(HDAC) inhibitors have been employed as anti-cancer agents for several
years, and a number of HDAC inhibitors are currently in clinical
trials. Although the exact mechanism by which HDAC inhibitors function
is unclear, it is believed that the ability of these molecules to
increase the expression of anti-cancer genes is behind their
therapeutic effect.
This invention concerns a means of improving specific cancer
therapy through the combination of (a) IL13-PE fusion proteins and (b)
HDAC inhibitors. The inventors surprisingly found that the expression
of IL13-R[alpha]2 increased in several types of pancreatic cancer cells
in response to HDAC inhibitors, whereas normal, healthy cells did not
experience such an increase in IL13-R[alpha]2 expression. The use of
IL13-PE fusion proteins in combination with HDAC inhibitors improved
specific killing of pancreatic cancer cells relative to the use of
IL13-PE fusion proteins in the absence of the HDAC inhibitors. This
suggested that the use of IL13-PE fusion proteins along with HDAC
inhibitors was a strong candidate combinatorial therapeutic for the
treatment of various cancers (e.g., pancreatic, glioblastoma
multiforme) and other diseases characterized by overexpression of IL13-
R[alpha]2 (e.g., asthma, pulmonary fibrosis).
Applications:
Treatment of diseases associated with the increased
expression of IL13-R[alpha]2
Relevant diseases include pulmonary fibrosis, asthma and
cancers such as pancreatic cancer, glioblastoma multiforme and other
head and neck cancers
Advantages:
HDAC inhibitors only increased IL13-R[alpha]2 expression
in diseased cells, leaving normal healthy cells unaltered
IL13-PE fusion proteins only kill cells that overexpress
IL13-R[alpha]2, allowing specific targeting of treatment
Targeted treatment decreases non-specific killing of
healthy, essential cells, resulting in fewer side-effects and healthier
patients
Development Status: Preclinical stage of development
Inventors: Puri et al. (FDA)
Patent Status: US provisional application 61/494,779 (HHS reference
E-107-2011/0-US-01)
For more information, see:
US Patents 5,614,191, 5,919,456 and 6,518,061 (HHS
technology reference E-266-1994/0)
US Patent Publication US 20040136959 A1 (HHS technology
reference E-032-2000/0)
US Patent 7,541,040 (HHS technology reference E-296-2001/
0)
Licensing Status: Available for licensing
Licensing Contact: David A. Lambertson, PhD; 301-435-4632;
[email protected]
Dated: July 26, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-19378 Filed 7-29-11; 8:45 am]
BILLING CODE 4140-01-P